{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:47:49Z","timestamp":1763203669480,"version":"3.45.0"},"publisher-location":"Cham","reference-count":35,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032084514","type":"print"},{"value":"9783032084521","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-08452-1_23","type":"book-chapter","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:43:55Z","timestamp":1763203435000},"page":"283-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Computational Analysis and Prediction of CYP1A2-Related Toxicants for Safer Drug Discovery"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8683-8459","authenticated-orcid":false,"given":"Yao","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7291-5160","authenticated-orcid":false,"given":"Uliano","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-3829","authenticated-orcid":false,"given":"Ivano","family":"Eberini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,16]]},"reference":[{"issue":"2","key":"23_CR1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/019262339502300202","volume":"23","author":"J Caldwell","year":"1995","unstructured":"Caldwell, J., Gardner, I., Swales, N.: An introduction to drug disposition: the basic principles of absorption, distribution, metabolism, and excretion. Toxicol. Pathol. 23(2), 102\u2013114 (1995)","journal-title":"Toxicol. Pathol."},{"issue":"3","key":"23_CR2","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3390\/livers3030032","volume":"3","author":"M Rai","year":"2023","unstructured":"Rai, M., et al.: Perspective on quantitative structure\u2013toxicity relationship (QSTR) models to predict hepatic biotransformation of xenobiotics. Livers 3(3), 448\u2013462 (2023)","journal-title":"Livers"},{"issue":"23","key":"23_CR3","doi-asserted-by":"publisher","first-page":"12808","DOI":"10.3390\/ijms222312808","volume":"22","author":"M Zhao","year":"2021","unstructured":"Zhao, M., et al.: Cytochrome P450 enzymes and drug metabolism in humans. Int. J. Mol. Sci. 22(23), 12808 (2021)","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"23_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/jox11030007","volume":"11","author":"F Esteves","year":"2021","unstructured":"Esteves, F., Rueff, J., Kranendonk, M.: The central role of cytochrome P450 in xenobiotic metabolism\u2014a brief review on a fascinating enzyme family. J. Xenobiot. 11(3), 94\u2013114 (2021)","journal-title":"J. Xenobiot."},{"issue":"1","key":"23_CR5","first-page":"129","volume":"2","author":"K Klein","year":"2010","unstructured":"Klein, K., Winter, S., Turpeinen, M., Schwab, M., Zanger, U.M.: Pathway-targeted pharmacogenomics of CYP1A2 in human liver. Front. Pharmacol. 2(1), 129 (2010)","journal-title":"Front. Pharmacol."},{"issue":"2","key":"23_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3109\/03602530903286476","volume":"42","author":"SF Zhou","year":"2010","unstructured":"Zhou, S.F., Wang, B., Yang, L.P., Liu, J.P.: Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab. Rev. 42(2), 268\u2013354 (2010)","journal-title":"Drug Metab. Rev."},{"issue":"1","key":"23_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s43188-020-00056-z","volume":"37","author":"FP Guengerich","year":"2021","unstructured":"Guengerich, F.P.: A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. Toxicol. Res. 37(1), 1\u201323 (2021)","journal-title":"Toxicol. Res."},{"issue":"23","key":"23_CR8","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.3748\/wjg.15.2817","volume":"15","author":"G Tarantino","year":"2009","unstructured":"Tarantino, G., Di Minno, M.N., Capone, D.: Drug-induced liver injury: is it somehow foreseeable? World J. Gastroenterol. WJG 15(23), 2817 (2009)","journal-title":"World J. Gastroenterol. WJG"},{"issue":"1","key":"23_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/FPC.0b013e32834c6efd","volume":"22","author":"CF Thorn","year":"2012","unstructured":"Thorn, C.F., Aklillu, E., Klein, T.E., Altman, R.B.: PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet. Genomics 22(1), 73\u201377 (2012)","journal-title":"Pharmacogenet. Genomics"},{"key":"23_CR10","unstructured":"Landrum, G.: RDKit: open-source cheminformatics (2006)"},{"issue":"1","key":"23_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/ci049714+","volume":"45","author":"JJ Irwin","year":"2005","unstructured":"Irwin, J.J., Shoichet, B.K.: ZINC\u2212 a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45(1), 177\u2013182 (2005)","journal-title":"J. Chem. Inf. Model."},{"issue":"4","key":"23_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/cbdd.13445","volume":"93","author":"JD Tyzack","year":"2019","unstructured":"Tyzack, J.D., Kirchmair, J.: Computational methods and tools to predict cytochrome P450 metabolism for drug discovery. Chem. Biol. Drug Des. 93(4), 377\u2013386 (2019)","journal-title":"Chem. Biol. Drug Des."},{"key":"23_CR13","unstructured":"Release S. 1: Maestro, Schr\u00f6dinger, LLC, New York, NY, 2024. Schr\u00f6dinger Release, January 2024"},{"issue":"86","key":"23_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.addr.2015.04.020","volume":"23","author":"L Olsen","year":"2015","unstructured":"Olsen, L., Oostenbrink, C., J\u00f8rgensen, F.S.: Prediction of cytochrome P450 mediated metabolism. Adv. Drug Deliv. Rev. 23(86), 61\u201371 (2015)","journal-title":"Adv. Drug Deliv. Rev."},{"key":"23_CR15","doi-asserted-by":"publisher","first-page":"E101","DOI":"10.1208\/aapsj080112","volume":"8","author":"FP Guengerich","year":"2006","unstructured":"Guengerich, F.P.: Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 8, E101\u2013E111 (2006)","journal-title":"AAPS J."},{"issue":"761","key":"23_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.mrgentox.2014.01.009","volume":"1","author":"M Fasullo","year":"2014","unstructured":"Fasullo, M., Smith, A., Egner, P., Cera, C.: Activation of aflatoxin B1 by expression of human CYP1A2 polymorphisms in Saccharomyces cerevisiae. Mutat. Res. Genetic Toxicol. Environ. Mutagen. 1(761), 18\u201326 (2014)","journal-title":"Mutat. Res. Genetic Toxicol. Environ. Mutagen."},{"issue":"2","key":"23_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1021\/tx025569n","volume":"16","author":"KS Smith","year":"2003","unstructured":"Smith, K.S., Smith, P.L., Heady, T.N., Trugman, J.M., Harman, W.D., Macdonald, T.L.: In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem. Res. Toxicol. 16(2), 123\u2013128 (2003)","journal-title":"Chem. Res. Toxicol."},{"key":"23_CR18","doi-asserted-by":"crossref","unstructured":"Sun, Q., Zhu, R., Foss Jr., F.W., Macdonald, T.L.: In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity. Chem. Res. Toxicol 21(3), 711\u2013719 (2008)","DOI":"10.1021\/tx7003085"},{"issue":"9","key":"23_CR19","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.bcp.2012.08.015","volume":"84","author":"Y Kobayashi","year":"2012","unstructured":"Kobayashi, Y., Fukami, T., Higuchi, R., Nakajima, M., Yokoi, T.: Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. Biochem. Pharmacol. 84(9), 1196\u20131206 (2012)","journal-title":"Biochem. Pharmacol."},{"issue":"1\u20132","key":"23_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0163-7258(96)00063-0","volume":"71","author":"L Verna","year":"1996","unstructured":"Verna, L., Whysner, J., Williams, G.M.: 2-Acetylaminofluorene mechanistic data and risk assessment: DNA reactivity, enhanced cell proliferation and tumor initiation. Pharmacol. Ther. 71(1\u20132), 83\u2013105 (1996)","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"23_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1006\/taap.2002.9398","volume":"181","author":"HG Shertzer","year":"2002","unstructured":"Shertzer, H.G., Dalton, T.P., Talaska, G., Nebert, D.W.: Decrease in 4-aminobiphenyl-induced methemoglobinemia in Cyp1a2 (\u2212\/\u2212) knockout mice. Toxicol. Appl. Pharmacol. 181(1), 32\u201337 (2002)","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"23_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/toxsci\/kfaa107","volume":"177","author":"G Gastelum","year":"2020","unstructured":"Gastelum, G., et al.: Polycyclic aromatic hydrocarbon-induced pulmonary carcinogenesis in cytochrome P450 (CYP) 1A1-and 1A2-null mice: roles of CYP1A1 and CYP1A2. Toxicol. Sci. 177(2), 347\u2013361 (2020)","journal-title":"Toxicol. Sci."},{"issue":"14","key":"23_CR23","first-page":"3043","volume":"55","author":"PV Nerurkar","year":"1995","unstructured":"Nerurkar, P.V., et al.: DNA adducts of 2-amino-3-methylimidazo [4, 5-f] quinoline (IQ) in colon, bladder, and kidney of congenic mice differing in Ah responsiveness and N-acetyltransferase genotype. Can. Res. 55(14), 3043\u20133049 (1995)","journal-title":"Can. Res."},{"issue":"11","key":"23_CR24","doi-asserted-by":"publisher","first-page":"4896","DOI":"10.1021\/jm300065h","volume":"55","author":"ST Orr","year":"2012","unstructured":"Orr, S.T., et al.: Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure\u2013activity relationships and discovery strategies to mitigate drug\u2013drug interaction risks. J. Med. Chem. 55(11), 4896\u20134933 (2012)","journal-title":"J. Med. Chem."},{"issue":"5","key":"23_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1021\/tx00035a009","volume":"6","author":"KL Kunze","year":"1993","unstructured":"Kunze, K.L., Trager, W.F.: Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6(5), 649\u2013656 (1993)","journal-title":"Chem. Res. Toxicol."},{"issue":"11","key":"23_CR26","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1124\/dmd.31.11.1352","volume":"31","author":"P Lu","year":"2003","unstructured":"Lu, P., Schrag, M.L., Slaughter, D.E., Raab, C.E., Shou, M., Rodrigues, A.D.: Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab. Dispos. 31(11), 1352\u20131360 (2003)","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"23_CR27","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1124\/dmd.106.011965","volume":"34","author":"MJ Karjalainen","year":"2006","unstructured":"Karjalainen, M.J., Neuvonen, P.J., Backman, J.T.: Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions. Drug Metab. Dispos. 34(12), 2091\u20132096 (2006)","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"23_CR28","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1046\/j.1365-2133.2001.04233.x","volume":"144","author":"I Tantcheva-Po\u00f3r","year":"2001","unstructured":"Tantcheva-Po\u00f3r, I., Servera-Llaneras, M., Scharffetter-Kochanek, K., Fuhr, U.: Liver cytochrome P450 CYP1A2 is markedly inhibited by systemic but not by bath PUVA in dermatological patients. Br. J. Dermatol. 144(6), 1127\u20131132 (2001)","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"23_CR29","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1021\/acs.chemrestox.2c00360","volume":"36","author":"G Ran","year":"2023","unstructured":"Ran, G., et al.: Mechanistic Study of Xanthotoxin-Mediated Inactivation of CYP1A2 and Related Drug-Drug Interaction with Tacrine. Chem. Res. Toxicol. 36(3), 420\u2013429 (2023)","journal-title":"Chem. Res. Toxicol."},{"key":"23_CR30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00228-001-0396-3","volume":"57","author":"X Wen","year":"2002","unstructured":"Wen, X., Wang, J.S., Neuvonen, P.J., Backman, J.T.: Isoniazid is a mechanism-based inhibitor of cytochrome P 450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur. J. Clin. Pharmacol. 57, 799\u2013804 (2002)","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"23_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/00498250802709428","volume":"39","author":"Q Zhu","year":"2009","unstructured":"Zhu, Q., Liao, J., Xie, L., Wang, G.J., Liu, X.D.: Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH2 derivative of levofloxacin in rats. Xenobiotica 39(4), 293\u2013301 (2009)","journal-title":"Xenobiotica"},{"issue":"6","key":"23_CR32","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/ptr.5285","volume":"29","author":"Y Zhao","year":"2015","unstructured":"Zhao, Y., Hellum, B.H., Liang, A., Nilsen, O.G.: Inhibitory mechanisms of human CYPs by three alkaloids isolated from traditional Chinese herbs. Phytother. Res. 29(6), 825\u2013834 (2015)","journal-title":"Phytother. Res."},{"issue":"2","key":"23_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1742-7843.2008.00252.x","volume":"103","author":"MJ Karjalainen","year":"2008","unstructured":"Karjalainen, M.J., Neuvonen, P.J., Backman, J.T.: In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin. Pharmacol. Toxicol. 103(2), 157\u2013165 (2008)","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"237","key":"23_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cbi.2015.06.018","volume":"25","author":"AH Yang","year":"2015","unstructured":"Yang, A.H., et al.: Identification and characterization of reactive metabolites in myristicin-mediated mechanism-based inhibition of CYP1A2. Chem. Biol. Interact. 25(237), 133\u2013140 (2015)","journal-title":"Chem. Biol. Interact."},{"issue":"1","key":"23_CR35","first-page":"5","volume":"1","author":"M Cui","year":"2020","unstructured":"Cui, M.: Introduction to the k-means clustering algorithm based on the elbow method. Account. Audit. Finance 1(1), 5\u20138 (2020)","journal-title":"Account. Audit. Finance"}],"container-title":["Lecture Notes in Computer Science","Bioinformatics and Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-08452-1_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:43:56Z","timestamp":1763203436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-032-08452-1_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,16]]},"ISBN":["9783032084514","9783032084521"],"references-count":35,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-08452-1_23","relation":{},"ISSN":["0302-9743","1611-3349"],"issn-type":[{"value":"0302-9743","type":"print"},{"value":"1611-3349","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,16]]},"assertion":[{"value":"16 November 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"IWBBIO","order":1,"name":"conference_acronym","label":"Conference Acronym","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"International Work-Conference on Bioinformatics and Biomedical Engineering","order":2,"name":"conference_name","label":"Conference Name","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Canaria","order":3,"name":"conference_city","label":"Conference City","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Spain","order":4,"name":"conference_country","label":"Conference Country","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"2025","order":5,"name":"conference_year","label":"Conference Year","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"16 July 2025","order":7,"name":"conference_start_date","label":"Conference Start Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"18 July 2025","order":8,"name":"conference_end_date","label":"Conference End Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"12","order":9,"name":"conference_number","label":"Conference Number","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"iwbbio2025","order":10,"name":"conference_id","label":"Conference ID","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"https:\/\/iwbbio.ugr.es","order":11,"name":"conference_url","label":"Conference URL","group":{"name":"ConferenceInfo","label":"Conference Information"}}]}}